Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/586,501 INFORMATION DISCLOSURE Filing Date September 14, 2007 STATEMENT BY APPLICANT First Named Inventor Martin Hendrix Art Unit 1624 (Use as many sheets as necessary) Deepak R. Rao Examiner Name

Chort				4	D / / / /		01-2118		
Sheet					, , , , , , , , , , , , , , , , , , , ,		2118		
	_				U.S. PA	TENT D	OCUMENTS		
Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (<i>if known</i>)		Publicatio		Name of Patentee or Gited Docum		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A1	US- 5 04	11 449		08-20-1991		BELLE A U E	Γ A L.	
	A 2	US- 5 047 407			09-10-	1991	BELLEAU E	Γ A L.	
	АЗ	US- 5 05	US- 5 053 499			1991	KOJI MA ET	AL.	
	A4	US- 5 27	70 315		12-14-	1993	BELLEA	J	
	A 5	US- 5 29	94 612		03-15-	1994	BACON ET	AL.	
	A 6	US- 5 46	36 806		11-14-	1995	BELLE A U E	ΓAL.	
	A 7	US- 5 54	11 187		07-30-	1996	BACON ET	AL.	
	A 8	US- 5 56	3 049		10-08-	1996	KOJI MA ET	AL.	
	A 9	US- 5 65	66 629		08-12-	1997	BACON ET	AL.	
	A 10	US- 5 68	34 164		11-04-	1997	BELLE A U E	Γ A L.	
	A11	US- 5 75	673		05-12-	1998	MARTIN		
	A12	US- 5 96	39 116		10-19-	1999	MARTIN		
	A13	US- 5 97	77 332		11-02-	1999	MARTIN		
	A14	US- 5 97	77 118		11-02-	1999	BACON ET AL.		
	A15	US- 6 10	0 037		08-08-2	2000	PHILLIPS E	ΓAL.	
	A 16	US- 6 17	75 008		01-16-2	2001	BELLEAU ET AL.		
	A17	US- 6 17	74 884		01-16-2	2001	HANING ET AL.		
	A 18	US- 6 21	11 158		04-03-2	2001	SEELA ET AL.		
	A 19	US- 6 22	25 315		05-01-2	2001	ELLIS		
	A 20	US- 200	1 0041	797	11-15-2	2001	BELLEAU ET AL.		
	A21	US- 200	1 0044	441	11-22-2	2001	CAMPBELL E	T AL.	
	A22	US- 6 35	50 753		02-26-2	2002	BELLEAU E	Γ A L.	
	A23	US- 200	2 0586	35	05-16-2	2002	AVERET	Т	
	A24	US- 200	2 0132	754	09-19-2	2002	BOSS ET A	AL.	
	A25	US- 6 45	58 796		10-01-2	2002	HANING ET	AL.	
	A 26	US- 6 47	79 463		11-12-2	2002	WANG ET	AL.	
	A27	US- 200	3 0087	918	05-08-2	2003	BELLE A U E	Γ A L.	
	A 28	US- 200	4 1854	59	09-23-2	2004	OTSUK A ET	AL.	
	A2 9	US- 200	4 0220	186	11-04-2	2004	BELL ET A	AL.	
	A 30	US- 6 83	31 174		12-14-2	2004	BELLE A U E	Γ A L.	
	A31	US- 200	4 0254	201	12-16-2	2004	BELLEAU ET AL.		
	A32	US- 6 90	3 224		06-07-2	2005	BELLEAU ET AL.		
	A33	US- 200	5 2092	51	09-22-2	2005	LINKER ET	AL.	
	A34	US- 7 73	37 156		05-11-2	2006	BOSS ET AL.		
	A 35	US- 7 06	57 507		06-27-2	2006	PULLEY ET	AL.	
	A 36	US- 7 12	US- 7 122 693		10-17-2006		BELLE A U E	Γ A L.	
	A37	US- 200	6 2586	51	11-16-2	2006	LINSCHOTEN ET AL.		
	A3 8	US- 200	7 0037	977	02-15-2	2007	BELLEAU E	ΓAL.	
	A 39	US- 200	7 0105	881	05-10-2	2007	HENDRIX E		
Examiner Signature							Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Benter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.' Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce. P.O.

this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450**, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known Application Number 10/586,501 INFORMATION DISCLOSURE Filing Date September 14, 2007 STATEMENT BY APPLICANT First Named Inventor Martin Hendrix Art Unit 1624 (Use as many sheets as necessary) Deepak R. Rao Examiner Name

Sheet	2	of 6			Attorney Docket Number		t Number	01-2118				
						U.S. PATI	ENT D	OCUME	NTS			
Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (<i>if known</i>)			Publication [MM-DD-YY			Patentee or Appl Cited Document	cant of	Pages, Columns, Lines, Where Passages or Relevar Figures Appear		
	A 40	US- 7 488	3 733			05-10-20	07	Н	ENDRIX ET AL			
	A41	US- 2009	01118	38		04-30-20	09	HI	ENDRIX ET AL			
	A 42	US- 2010	00359	00		02-11-20	10	HI	ENDRIX ET AL			
	A43	US- 2010	02108	39		08-19-20	10	Е	BOESS ET AL.			
	A44	US- 2011	00151	93		01-20-20	11	EIC	KMEIER ET A	L.		
	A 45	US- 2011	00657	30		03-17-20	11	HI	ENDRIX ET A L			
	A 46	US- 2011	00821	37		04-07-20	11	GIC	VANNINI ET A	.L.		
					F	OREIGN P	ATEN	T DOCL	MENTS			
Examiner Initials*	Cite No. ¹	Foreign Country (ument per ⁴ – Kind	Code ⁵ (if		olication Date DD-YYYY	Name of Pat Applicant o Docum	of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁶
	B1			GB-	937 724		09-2	25-1963	CIBA L	.TD		
	B2			CH-	396 924		08-1	5-1965	CIBA GI	EIGY		A 34
	В3			CH-	396 925		08-1	5-1965	CIBA GEIGY			A34
	B4		EP-0 130 735			01-0	9-1985	AMERICAN HOME PROD				
	B5		[EP-0	286 028		10-1	10-12-1988 BOEHRIN MANNHEIN		I GMBH		B8
	В6		DE-4 004 558				09-2	27-1990	SANYO KOKUSAKU PULP CO			АЗ
	B7		EP-496 617						GENSIA PI			
	B8		(CA-1	311 201		12-0	8-1992	MANNHEIM GMB			
	В9				94 14802			7-1994	BELLEAU PIERRETTE & HF			
	B10				94 17803		1	8-1994	GENSIA INC			
	B11				626 387		_	30-1994	CIBA GEIGY AG			
	B12			EP-0	679 657		11-0	2-1995	CIBA GEIGY AG			A11
	B13				97 16456		1	9-1997	CHONG KUN DANG CORP			
	B14				97 46569		_	1-1997	CIBA GEIGY AG			
	B15	1			98 00434		1	08-1998	CIBA GEI			
	B16		WO-98 16184				23-1998	PHARMACE				
	B17	WO-98 40384			09-1	7-1998	BAYER					
	B18	JP-11-501923				02-1	6-1999	SANOFI WINTHROP INC.				
	B19		WO-2000 04339			94	4 07-27-		USTAV EXPERIMTALRI BOTANIKY AV CR			
	B20		WO-2001 0575			8	01-2	25-2001	NPS ALLELIX CORP			
	B21		WO-2001 060315		15	08-2	23-2001	BIOCHEM F	PHARMA			
Examiner Signature								Date Consid	ered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Viral of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/586,501 INFORMATION DISCLOSURE Filing Date September 14, 2007 STATEMENT BY APPLICANT First Named Inventor Martin Hendrix Art Unit 1624 (Use as many sheets as necessary) Examiner Name Deepak R. Rao Sheet 3 of 6 Attorney Docket Number 01-2118

		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No. ¹	Country Code ³ – Number ⁴ – Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т ⁶
	B22	JP- 2001 514638	09-11-2001	BAYER AG		A17
	B23	WO-2001 077075	10-18-2001	INOTEK CORP		
	B24	WO-2002 16348	02-28-2002	ASTRAZENECA AB		
	B25	WO-2002 057425	07-25-2002	MERCK & CO INC		
	B26	JP-2002 523507	07-30-2002	Bayer AG		A25
	B27	WO-2002 074774	09-26-2002	PFIZER LTD		
	B28	WO-2002 086160	10-31-2002	MITSUBISHI RAYON CO		A 28
	B29	W O-2003 011925	02-13-2003	PPG IND OHIO INC		
	B30	WO-2003 022859	03-20-2003	EPOCH BIOSCIENCES INC		
	B31	CA- 2 466 824	05-08-2003	PFIZER		
	B32	WO-2003 037432	05-08-2003	PFIZER PROD INC		
	B33	WO-2003 072757	09-04-2003	BIOTA INC		
	B34	WO-2003 099840	12-04-2003	ISIS PHARMACEUTICALS INC		
	B35	WO-2004 002999	01-08-2004	IDENIX CAYMAN LTD		
	B36	CA-2 496 194	03-04-2004	BAYER HEALTHCARE AG		
	B37	DE-102 38 722	03-11-2004	BAYER AG		A34
	B38	WO-2004 046331	06-03-2004	IDENIX CAYMAN LTD		
	B39	EP-1 460 077	09-22-2004	JORDANIAN PHARMACEUTICAL MFG		
	B40	JP-2004 536933	12-09-2004	PPG IND OHIO INC		B29
	B41	W O-2004 108139	12-16-2004	AREXIS AB		A37
	B42	WO- 2004 113306	12-29-2004	BAYER HEALTHCARE AG		A 40
	B43	WO-2005 051944	06-09-2005	UNIV CONNECTICUT		
	B44	JP-2005 531549	10-20-2005	BAYER CROPSCIENCE AG		A33
	B45	JP-2006 201272	01-12-2006	TAMURA SEISAK		A34
	B46	JP-2006 503051	01-26-2006	BAYER AG		
	B47	WO-2006 076455	07-20-2006	ARENA PHARM INC.		
	B48	WO-2006 084281	08-10-2006	MILLENNIUM PHARM INC		
	B49	WO-2006 091905	08-31-2006	GILEAD SCIENCES INC		
	B50	WO-2006 125548	11-30-2006	BAYER HFALTHCARF AG		C9

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

WIPU Standard s 1. To It possible. "Applicant is to place a check mark here it English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO						Complete if Known							
					Applic	ation Nun	nber		10/586	5,501			
INFO	DRMA	TION [DIS	CLOSURE	Filing	Date			Septer	nber 14, 2007			
STA	TEME	NT BY	/ AI	PPLICANT	First Named Inventor Art Unit			一	Martin Hendrix				
• • • • • • • • • • • • • • • • • • • •								_					
	(Use as	many shee	ts as	necessary)	Examiner Name				Deepa	k R. Rao			
Sheet	4		of	6	Attorn	ey Docke	t Number		01-211				
				FOREIGN P	ATEN	T DOCL	MENTS						
		Foreign P	atent	Document				f Patent	00 0r	Pages, Columns, Lines,			
Examiner Initials*			ode³ – ſ	Number ⁴ – Kind Code ⁵ (<i>if</i>		elication Date DD-YYYY	Applica	ant of Ci ocument	ited	Where Relevant Passages or Relevant Figures Appear	T^6		
	B51		W	D-2007 025043	03-0	1-2007	PHARMA	DENIX ACEUT INC	ICALS				
	B52		W	D-2007 046747	04-2	6-2007	ASTRAZ		A AB				
	B53		W	D-2008 005542	01-1	0-2008	GILEAD	SCIEN	NCES				
	B54		W	D-2008 055959	05-1	5-2008	GALAP		N V				
	B55		W	D-2008 100447	08-2	1-2008	GILEAD	SCIEN	NCES				
	B56		W	D-2008 104077	09-0	4-2008	METHY		E INC				
	B57		W	D-2008 139293	11-2	0-2008	PI	FIZER					
	B58		W	D-2009 068617	06-0	4-2009	INGEL	HRINGI _HEIM	INT				
	B59		W	D-2009 121919	10-0	8-2009		HRINGI _HEIM					
	B60		W	D-2010 026214	03-1	1-2010	BOEH INGEL	HRINGI _HEIM	ER INT				
	B61		WO-2010 112437		10-0	7-2010	INGEL	HRINGI _HEIM	INT				
	B62		WC)- 2011 018495	02-1	7-2011		HRINGI _HEIM					
				NON PATENT LI	TERA	TURE D	OCUME	NTS					
Examiner Initials *	Cite			me of the author (in CAF book, magazine, journal, number(s), pub	serial, s	ymposiu	m, catalog	g, etc.)	, date, ¡	page(s), volume-issue	T ²		
	C1	Accesse	ed on l	December 18, 2008, http://e					•				
	C2	Accesse	ed on I	December 18, 2008, www.m	nentalhea	lth.org.uk/	information	ı/menta	ıl-health-	a-z/dementia			
	С3			AL., "Role of cyclic GMP in t Precursor," J of Neurochem						val by Secreted Forms of			
	C4	BYRN E	T AL.	Solid State Chemistry of D	rugs, 199	99, Second	l Edition, C	hapter	11, pp. 2	32-247			
	C5	Chem A	bstrac	ts Service, Database Acces	sion No.	ALB-H016	377136, Da	tabase	Chemca	ats, 2007, XP002556399			
	C6	Impairm	ent in	AL., "Cortical Pyramidal Net Alzheimer's Disease: Inves pp. 1589-1604							,		
	C7	FRANCI	IS ET	AL., "Glutamatergic system: p. S15-21	s in A lzhe	eimer's dis	ease," Inter	rnation	al Journa	al of Geriatric Psychology,			
Examiner Signature						Date Consid	ered				, ,		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTC	1		Complete if Known			
				Application Number	10/586,501		
INFO	RMATION	DIS	CLOSURE	Filing Date	September 14, 2007		
STAT	EMENT B	Υ ΑΙ	PPLICANT	First Named Inventor	Martin Hendrix		
(Use as many sheets as necessary)				Art Unit	1624		
				Examiner Name	Deepak R. Rao		
Sheet	5	of	6	Attorney Docket Number	01-2118		

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of						
Examiner Initials *	Cite No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T					
	C8	HARB ET AL., "Pyrazoles as building blocks in heterocyclic synthesis," Chemical Papers, 2005, Vol. 59, No. 3, pp. 187-195, XP002498868						
	C9	HENDRIX, M. ET AL., "Use of pyrazolopyrimidine against cardiovascular diseases," Data retrieved from espacenet worldwide database, Publication Date: November 30, 2006; English Abstract of WO-2006 125548						
	C10	HETMAN ET AL., "Isolation and characterization of PDE7B, a" Proc. Nat. Acad. Sci., 2000, Vol. 97, No. 1, pp. 472-476						
	C11	HUNG ET AL., "A high-yielding synthesis of monalkylhydrazines," Journal of Organic Chemistry, 1981, Vol. 46, pp. 5413-5414						
	C12 International Search Report of PCT/EP2003/08880 dated April 1, 2004, International Filing Date: August 11, 2011 International Publication No. WO 2004 026286							
	C13	Last accessed July 15, 2010http://www.nlm.nih.gov/medlineplus/ency/article/000746.htm						
	C14	MARKWALDER, J. A. ET AL., "Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1H-pyrazolo[3.4-d]pyrimidin-4-one Inhibitors of Cyclin-Dependent Kinases," J of Med Chemistry, 2004, Vol. 47, pp. 5894-5911, XP002399637						
	C15	PRICKAERTS ET AL., "Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic gmp levels in the rat," Neuroscience, 2002, Vol. 113, No. 2, pp. 351-361						
	C16	PUZZO ET AL., "Amyloid-Beta Peptide Inhibits Activation of the Nitric Oxide/Cgmp/Camp-Responsive Element-						
	C17	Related U.S. Patent Application No. 12/855,129 filed August 12, 2010						
	C18	Related U.S. Patent Application No. 12/935,686 filed September 30, 2010						
	C19	Related U.S. Patent Application No. 13/062,625 filed March 7, 2011						
	C20	Related U.S. Patent Application No. 13/099,064 filed May 2, 2011						
	C21	REYMANN ET AL., "The late maintenance of hippocampal LTP: Requirements, phases, 'synaptic tagging', 'late-associativity' and implications," Neuropharmacology, 2007, Vol. 52, pp. 24-40						
	C22	SKIPPER ET AL., "Structure-Activity Relationships Observed on Screening a Series of Pyrazolopyrimidines against Experimental Neoplasms," Cancer Research, 1957, Vol. 17, pp. 579-596						
Examiner Signature		SKIPPER ET AL., "Structure-Activity Relationships Observed on Screening a Series of Pyrazolopyrimidines	_					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/586,501 INFORMATION DISCLOSURE Filing Date September 14, 2007 STATEMENT BY APPLICANT First Named Inventor Martin Hendrix Art Unit 1624 (Use as many sheets as necessary) Deepak R. Rao Examiner Name Sheet 6 of 6 Attorney Docket Number 01-2118

		NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	C23	TIMBERLAKE ET AL., "Chemistry of Hydrazo-, Azo-, and Azoxy Groups," Patai, 1975, Chapter 4							
	C24	UGARKAR ET AL., "Synthesis and antiviral/antitumor activities of," Journal of Medicinal Chemistry, 1984, Vol. 27, No. 8, pp. 1026-1030							
	C25 VAN STAVEREN ET AL., Journal of Neurocytology, 2002, Vol. 31, pp. 729-741								
	C26	WANG ET AL., "Identification and characterization of a new human type 9 Cgmp-specific phosphodiesterase-splice variant (PDE9A5) Different tissue distribution and subcellular localization of PDE9A variants," Gene, 2003, Vol. 314, pp. 15-27							
Examiner Signature		Date Considered							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the patent document by the appropriate symbols as indicated on the document will be standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450,** Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.